Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-1
SponsorLe Bonheur Children's Hospital

About this trial

Hospitalized infants with severe bronchopulmonary dysplasia (BPD) and feeding intolerance will be randomized to 2 weeks of continuous gastric feeding or continuous transpyoloric feeding. Subjects will crossover after 2 weeks and receive 4 weeks of each feeding mode. Respiratory status will be assessed to determine the optimal feeding mode for each infant.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients born <32 weeks' gestation

Currently admitted to the Le Bonheur NICU

Grad 2 or 3 BPD (positive pressure or intubated at 36 weeks PMA)

Signs of gastroesophageal reflux, chronic aspiration, or other feeding intolerance.

Disqualifiers

Known gastrointestinal anomalies

Unable to tolerate ≥100mL/kg/day enteral feeding

Congenital anomalies likely to alter feeding techniques

Surgical feeding tube in place or expected within the next 8 weeks

Trial design

Design model

Crossover

Treatments tested in this trial

  • Gastric feeding

    Procedure/Surgery

    Subjects will be fed through a feeding tube that empties into the stomach.

  • Transpyloric feeding

    Procedure/Surgery

    Subjects will be fed through a feeding tube that passes through the stomach and empties directly into the small intestine.

Treatment groups

25 Participants
are divided into 2 treatment groups
Group A: Gastric feedingActive comparator 1 intervention
Group B: Transpyloric feedingActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Respiratory Severity Score (RSS)

RSS (the product of mean airway pressure and oxygen fraction) will be calculated before and after each 2-week intervention block.

Time frame
8 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.